GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OTCPK:CLPBY) » Definitions » Selling and Marketing Expense

CLPBY (Coloplast AS) Selling and Marketing Expense : $1,330 Mil (TTM As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Coloplast AS Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Coloplast AS's Selling and Marketing Expense for the three months ended in Mar. 2025 was $337 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $1,330 Mil.


Coloplast AS Selling and Marketing Expense Historical Data

The historical data trend for Coloplast AS's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS Selling and Marketing Expense Chart

Coloplast AS Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 841.98 867.80 904.22 1,075.89 1,313.64

Coloplast AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 313.71 324.65 341.17 327.01 337.14

Coloplast AS Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,330 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast AS Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Coloplast AS's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

From GuruFocus

Q2 2021 Coloplast A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q4 2024 Coloplast A/S Earnings Call Transcript

By GuruFocus News 11-06-2024

Q4 2022 Coloplast A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2024 Coloplast A/S Earnings Call Transcript

By GuruFocus Research 08-21-2024

Coloplast A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Q3 2021 Coloplast A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024